A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer

NCT02232633 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma
Cholangiocarcinoma

Interventions

DRUG: BBI503

Sponsor

Sumitomo Pharma America, Inc.